BrightGene Bio-Medical Technology Co., Ltd. (SHA: 688166)

Market Cap	12.47B
Revenue (ttm)	1.24B
Net Income (ttm)	188.08M
Shares Out	422.10M
EPS (ttm)	0.45
PE Ratio	65.82
Forward PE	58.81
Dividend	0.10 (0.32%)
Ex-Dividend Date	n/a

Volume	8,666,442
Open	30.50
Previous Close	29.66
Day's Range	30.11 - 31.20
52-Week Range	19.63 - 41.39
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 3, 2025

About BrightGene Bio-Medical Technology

BrightGene Bio-Medical Technology Co., Ltd., a pharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products in China. The company offers Eribulin mesylate injection, Voriconazole for injection, Entecavir tablets, Oseltamivir phosphate capsule and dry suspension, Agatroban injection, Mikafungin sodium for injection, Fondaparinux sodium injection, and Caspofungin acetate for injection. It also provides antitumor, antibodies drug conjugate, anti-infection, angiography, gynecology, c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 1,155
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688166

Financial Performance

In 2023, BrightGene Bio-Medical Technology's revenue was 1.18 billion, an increase of 15.94% compared to the previous year's 1.02 billion. Earnings were 202.47 million, a decrease of -15.51%.